NON-SMALL CELL LUNG CANCER (NSCLC), EGFR DOWNSTREAM PATHWAY ACTIVATION AND TKI TARGETED THERAPIES SENSITIVITY: EFFECT OF THE PLASMA MEMBRANE-ASSOCIATED NEU3.

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.

Adenocarcinoma of Non-Small Cell Lung Cancer (NSCLC) is a severe disease.Patients carrying EGFR mutations may benefit from EGFR targeted therapies (e.g.: gefitinib).Recently, it has been shown that sialidase NEU3 directly interacts and regulates EGFR.In this work, we investigate the effect of sialidase NEU3 overexpression on EGFR pathways activatio

read more

Evaluation of the Antimicrobial Peptide, RP557, for the Broad-Spectrum Treatment of Wound Pathogens and Biofilm

The relentless growth of multidrug resistance and generation of recalcitrant biofilm are major obstacles in treating wounds, particularly in austere military environments where broad-spectrum pathogen coverage is needed.Designed antimicrobial peptides (dAMPs) are constructed analogs of naturally occurring AMPs that provide the first line of defense

read more


Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment

Given significant genetic, molecular, and phenotypic overlaps, researchers have begun to investigate whether targeted treatments for Fragile X Syndrome (FXS) could also be beneficial for patients with Autism Spectrum Disorder (ASD).For example, low-dose sertraline, an SSRI, was used in two recent controlled trials in children with FXS and ASD.The f

read more